BioSpace News Archive

Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the third quarter of 2023 of $1.19 per share on the company’s common stock.

BBI-001 was well tolerated with no dose limiting toxicities. Single-dose administration demonstrated a statistically significant reduction of dietary iron absorption.

Genentech, a member of the Roche Group, announced that data from its ophthalmology portfolio will be highlighted in 25 abstracts at the 2023 American Society of Retina Specialists Annual Meeting, which will be held from July 28 to August 1 in Seattle, WA.

Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and interim report for January to June 2023.

Sosei Group Corporation, will hold an investor and press conference on ’s announcement; “Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC, Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company.”

Sosei Group Corporation announces that it has resolved, at a meeting of the Board of Directors held on 20 July 2023, to acquire from Idorsia Ltd and Idorsia Pharmaceutical Ltd all shares of Idorsia Pharmaceuticals Japan Ltd and Idorsia Pharmaceuticals Korea Co., Ltd .

LimmaTech Biologics AG signed an in-license agreement with GlaxoSmithKline Biologicals SA enabling LimmaTech Bio to further develop and commercialize a quadrivalent bioconjugate vaccine candidate for shigellosis that GSK added to its infectious disease pipeline when LimmaTech Bio’s predecessor company, GlycoVaxyn, was acquired by GSK in 2015.

CatalYm announced the publication of preclinical data in Nature Communications under the title “Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment”.

Aurinia Pharmaceuticals Inc. announced that it will release financial and operational results for the second quarter of 2023, on Thursday, August 3, 2023, before markets open.

Pasithea Therapeutics Corp. confirmed that an independent special committee of its Board of Directors thoroughly reviewed and rejected an unsolicited, non-binding proposal from Lucy Scientific Discovery, Inc. to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock.